Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

Novartis day

Novartis changes focus in Shanghai from early research to drug development

Swiss pharma switches focus of $1bn R&D institute

- PMLiVE

Alkermes boosts CNS presence with $950m Rodin acquisition

Follows company making job cuts in September as part of cost-saving efforts

- PMLiVE

Biogen under fire over $88,000 Vumerity annual price

Pricing pressure levelled at Tecfidera follow-up MS drug

- PMLiVE

Rethinking trials: the pros and cons of protocol amendments

Protocol amendments occur often and can be beneficial, but the steps involved can be complex

- PMLiVE

Don’t we all need to be able to change something?

Surely no one plans for a ‘life of easy’, where nothing happens. Easy sounds good, but surely life’s challenges present the opportunity to shine (even fail, with the chance to...

- PMLiVE

Antibiotic resistance: The silent pandemic

Porterhouse is proud to support World Antibiotic Awareness Week. Our article aims to improve awareness of one of the biggest threats to global health today: antibiotic resistance.

Porterhouse Medical Group

Roche Basel Switzerland

Roche agrees $1.4bn takeover of fibrosis specialist Promedior

Portfolio includes phase 2 candidate with FDA breakthrough status

Celgene building

UPDATED: BMS completes Celgene merger after FTC okay

Approval comes over ten months after acquisition announcement

- PMLiVE

Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations

Sanofi Genzyme’s Lemtrada and Pfizer's Xeljanz receive label restrictions

- PMLiVE

The NHS is facing shortages of lifesaving treatments, says internal document

Identifies 17 new shortages including drugs for cancer treatment

- PMLiVE

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

First wave of new molecular entities has potential to generate 14 approvals

- PMLiVE

BeiGene bags FDA approval for first product Brukinsa in lymphoma

Also the first approval for a Chinese-developed cancer drug in US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links